Search | IOVS | ARVO Journals

Showing 1 – 20 of 31

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

Progression of Stargardt disease as measured by spectral-domain optical coherence tomography (SD-OCT) in the ProgStar Study

Rupert Wolfgang Strauss; Xiangrong Kong; Beatriz E Munoz; Sheila K West; Michael S Ip; Alexander Ho; Anamika Jha; Paul S Bernstein; David G Birch; Artur V Cideciyan; Michel Michaelides; José-Alain Sahel; Janet S Sunness; Elias I Traboulsi; Eberhart Zrenner; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1568.

ARVO Annual Meeting Abstract July 2018

Reproducibility of a Modified Dual Grading Model Applied to Fundus Autofluorescence Measurements in Macular Atrophy Secondary to Stargardt Disease

Cynthia S. Chan; Alexander Ho; Dennis Jenkins; Sean Pitetta; Manfred Li; Jennifer Tassy; Rupert Wolfgang Strauss; Hendrik P Scholl; Srinivas R. Sadda; Michael S Ip

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3143.

ARVO Annual Meeting Abstract July 2018

Static and dynamic assessment of fixation stability in Stargardt disease

Etienne M Schonbach; Artur V Cideciyan; Mohamed A Ibrahim; Rupert Wolfgang Strauss; David G Birch; Janet S Sunness; Srinivas R. Sadda; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):788.

ARVO Annual Meeting Abstract June 2017

Natural progression of scotopic and photopic macular function loss in patients with Stargardt disease: The SMART Study.

Millena Bittencourt; Mohamed A Ibrahim; Xiangrong Kong; Rupert Wolfgang Strauss; Ann-Margret Ervin; Alexander Ho; Muneeswar Gupta Nittala; Isabelle S Audo; David G Birch; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3281.

ARVO Annual Meeting Abstract June 2017

Genetic characteristics of an international large cohort with Stargardt disease: The ProgStar study

Kaoru Fujinami; Rupert Wolfgang Strauss; John Chiang; Isabelle S Audo; Paul S Bernstein; David G Birch; Samuel G Jacobson; Brian C Mansfield; Meghan J Marino; Jose Alain Sahel; Saddek Mohand-Said; Janet S Sunness; Elias I Traboulsi; Eberhart Zrenner; Michel Michaelides; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4638.

ARVO Annual Meeting Abstract June 2017

Visual acuity loss during two years in Stargardt Disease: The ProgStar Study

Xiangrong Kong; Rupert Wolfgang Strauss; Beatriz Munoz; Ann-Margret Ervin; Artur V Cideciyan; Michel Michaelides; Mohamed Ahmed; Janet Cheetham; Sheila West; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4647.

ARVO Annual Meeting Abstract June 2017

Progression of Atrophic Lesions Determined by Fundus Autofluorescence: The Natural History of the Progression of Atrophy secondary to Stargardt Disease (ProgStar) Study

Rupert Wolfgang Strauss; Xiangrong Kong; Alex Ho; Anamika Jha; Michel Michaelides; Artur V Cideciyan; Jose Alain Sahel; David G Birch; Amir H Hariri; Srinivas R Sadda; Sheila West; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2013.

ARVO Annual Meeting Abstract June 2017

Month 18 changes in microperimetric mean sensitivity, fixation location, and fixation stability in Stargardt disease: The ProgStar Study

Etienne Schonbach; Xiangrong Kong; Mohamed A Ibrahim; Rupert Wolfgang Strauss; David G Birch; Artur V Cideciyan; Muneeswar Gupta Nittala; Janet S Sunness; Eberhart Zrenner; Srinivas R Sadda; Sheila West; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4635.

ARVO Annual Meeting Abstract June 2017

Changes in choroidal vasculature predict visual outcomes in Stargardt disease

Alexander Ho; Siva Balasubramanian; Anamika Jha; Beatriz Munoz; Rupert Wolfgang Strauss; Michael S Ip; Srinivas R Sadda; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4637.

ARVO Annual Meeting Abstract June 2017

Progression of Stargardt disease as measured by spectral-domain optical coherence tomography (SD-OCT) in the ProgStar Study

Mohamed A Ibrahim; Yulia Wolfson; Beatriz Munoz; Rupert Wolfgang Strauss; Sheila West; Swetha Velaga; Nizar Saleh Abdelfattah; Jianyan Huang; Srinivas R Sadda; David G Birch; Eberhart Zrenner; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4640.

ARVO Annual Meeting Abstract September 2016

Impact of segmentation density on spectral domain optical coherence tomography (SD-OCT) assessments in Stargardt disease.

Anamika Jha; Alexander Ho; Muneeswar gupta Nittala; Rupert Wolfgang Strauss; Hendrik P Scholl; Srinivas R Sadda

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2691.

ARVO Annual Meeting Abstract September 2016

Repeatability of contrast testing and the comparison of contrast sensitivity between normal and glaucomatous eyes

Simrat K Sodhi; Saghar Bagheri; Yulia Wolfson; Pradeep Y Ramulu; Pujan Dave; Luis A Lesmes; Emma McDonnell; Rupert Wolfgang Strauss; David S Friedman; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):617.

ARVO Annual Meeting Abstract September 2016

Results from spectral-domain optical coherence tomography (SD-OCT) at baseline compared with normative data: The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study

Alexander Ho; Beatriz E Munoz; Rupert Wolfgang Strauss; Anamika Jha; Ngoc Lam; Zhihong Hu; David G Birch; Eberhart Zrenner; Sheila K West; Srinivas R Sadda; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2697.

ARVO Annual Meeting Abstract September 2016

Associations between fundus autofluorescence and spectral-domain optical coherence tomography in Stargardt disease at baseline of the prospective ProgStar study.

Yulia Wolfson; Beatriz E Munoz; Rupert Wolfgang Strauss; Alexander Ho; Anamika Jha; Elias I Traboulsi; Artur V Cideciyan; Michel Michaelides; Srinivas R Sadda; Sheila K West; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract September 2016

Cross-sectional evaluation of microperimetric fixation location and stability in Stargardt disease in the ProgStar study

Etienne M. Schonbach; Mohamed A Ibrahim; Rupert Wolfgang Strauss; Xiangrong Kong; Alexander Ho; Paul S Bernstein; Janet S Sunness; Eberhart Zrenner; Srinivas R Sadda; Sheila K West; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2694.

ARVO Annual Meeting Abstract September 2016

The natural history of the progression of atrophy secondary to Stargardt disease type 4 (Progstar-4 Study): Baseline demographics and ocular characteristics of patients with PROM-1 related retinal dystrophy.

Syed Mahmood Ali Shah; Mohamed Ahmed; Nadia Junaid; Saghar Bagheri; Beatriz E Munoz; Rupert Wolfgang Strauss; Etienne M. Schonbach; Michel Michaelides; Ann-Margret Ervin; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2695.

ARVO Annual Meeting Abstract September 2016

Scotopic and photopic macular functions as assessed with microperimetry (MP1) in patients with Stargardt disease type 1 – The SMART Study

Mohamed A Ibrahim; Rupert Wolfgang Strauss; Xiangrong Kong; Ann-Margret Ervin; Alexander Ho; Janet S Sunness; Isabelle S Audo; David G Birch; Srinivas R Sadda; Millena G Bittencourt; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2696.

ARVO Annual Meeting Abstract September 2016

Six-month-change in microperimetric mean sensitivity, fixation location and fixation stability in Stargardt disease: The prospective ProgStar study

Shazia Khan; Xiangrong Kong; Rupert Wolfgang Strauss; Mohamed A Ibrahim; Etienne M. Schonbach; Saddek Mohand-Said; Michel Michaelides; David G Birch; Janet S Sunness; Srinivas R Sadda; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract September 2016

Progression of atrophic lesions prospectively determined by fundus autofluorescence: the natural history of the progression of atrophy secondary to Stargardt disease (ProgStar) study

Rupert Wolfgang Strauss; Xiangrong Kong; Anamika Jha; Paul S Bernstein; Michel Michaelides; Jose Sahel; Elias I Traboulsi; Eberhart Zrenner; Sheila K West; Srinivas R Sadda; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract September 2016

Visual acuity loss during one year in Stargardt Disease: ProgStar Prospective Study

Xiangrong Kong; Rupert Wolfgang Strauss; Ann-Margret Ervin; Paul S Bernstein; Artur V Cideciyan; Janet S Sunness; Elias I Traboulsi; Beatriz E Munoz; Mohamed Ahmed; Sheila K West; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Specify Date Range

Progression of Stargardt disease as measured by spectral-domain optical coherence tomography (SD-OCT) in the ProgStar Study

Reproducibility of a Modified Dual Grading Model Applied to Fundus Autofluorescence Measurements in Macular Atrophy Secondary to Stargardt Disease

Static and dynamic assessment of fixation stability in Stargardt disease

Natural progression of scotopic and photopic macular function loss in patients with Stargardt disease: The SMART Study.

Genetic characteristics of an international large cohort with Stargardt disease: The ProgStar study

Visual acuity loss during two years in Stargardt Disease: The ProgStar Study

Progression of Atrophic Lesions Determined by Fundus Autofluorescence: The Natural History of the Progression of Atrophy secondary to Stargardt Disease (ProgStar) Study

Month 18 changes in microperimetric mean sensitivity, fixation location, and fixation stability in Stargardt disease: The ProgStar Study

Changes in choroidal vasculature predict visual outcomes in Stargardt disease

Progression of Stargardt disease as measured by spectral-domain optical coherence tomography (SD-OCT) in the ProgStar Study

Impact of segmentation density on spectral domain optical coherence tomography (SD-OCT) assessments in Stargardt disease.

Repeatability of contrast testing and the comparison of contrast sensitivity between normal and glaucomatous eyes

Results from spectral-domain optical coherence tomography (SD-OCT) at baseline compared with normative data: The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study

Associations between fundus autofluorescence and spectral-domain optical coherence tomography in Stargardt disease at baseline of the prospective ProgStar study.

Cross-sectional evaluation of microperimetric fixation location and stability in Stargardt disease in the ProgStar study

The natural history of the progression of atrophy secondary to Stargardt disease type 4 (Progstar-4 Study): Baseline demographics and ocular characteristics of patients with PROM-1 related retinal dystrophy.

Scotopic and photopic macular functions as assessed with microperimetry (MP1) in patients with Stargardt disease type 1 – The SMART Study

Six-month-change in microperimetric mean sensitivity, fixation location and fixation stability in Stargardt disease: The prospective ProgStar study

Progression of atrophic lesions prospectively determined by fundus autofluorescence: the natural history of the progression of atrophy secondary to Stargardt disease (ProgStar) study

Visual acuity loss during one year in Stargardt Disease: ProgStar Prospective Study

To View More...

You must be signed into an individual account to use this feature.